Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

COHERE will track long-term effects of beta-blockade in heart failure

Oct. 14, 1998

Antiatherogenic activity of antioxidant BO-653 explored in animal models

Oct. 13, 1998

Antiatherosclerotic compounds prepared by Bayer scientists

Oct. 13, 1998

Verelan and Verelan PM licensed to Schwarz for U.S.

Oct. 9, 1998

European academic researchers disclose nonxanthine adenosine receptor antagonists

Oct. 9, 1998

Endothelin antagonists for hypertension in development at Tanabe Seiyaku

Oct. 9, 1998

Long-term ETA receptor blockade shows detrimental effects on LV remodeling

Oct. 8, 1998

Dual TxA2 antagonists and NO donors and their use disclosed by ADIR

Oct. 8, 1998

Inex, Schwarz drop development of antisense drug for restenosis

Oct. 5, 1998

IRL-3630, a bifunctional ETA/ETB receptor antagonist in preliminary testing at Novartis

Oct. 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...